Avant Immunotherapeutics Inc Quarterly Income Statement Display Annual Data 
More filings for Avant Immunotherapeutics Inc available from EDGAR 0nline.  Get a Free Trial to EDGAR Online Premium  
 
Income Statement   Balance Sheet   Cash Flow Statement   
  
Period Ending: Sep 30, 2001 Jun 30, 2001 Mar 31, 2001 Dec 31, 2000 
Total Revenue $725,400 $825,800 $859,000 $301,600 
Cost Of Revenue $8,400 $8,200 $10,100 $10,100 
Gross Profit $717,000 $817,600 $848,900 $298,100 
 
Operating Expenses 
    Research And Development $5,633,000 $5,525,700 $3,976,700 $12,713,800 
    Selling General And Administrative Expenses $1,321,700 $1,112,700 $1,214,300 $1,613,500 
    Non Recurring N/A N/A N/A N/A 
    Other Operating Expenses $194,300 $56,300 ($92,400) ($351,200) 
 
Operating Income ($6,581,700) ($6,164,900) ($4,686,000) ($14,235,300) 
Total Other Income And Expenses Net $357,700 $494,900 $682,400 $741,200 
Earnings Before Interest And Taxes ($6,224,000) ($5,670,000) ($4,003,600) ($13,494,100) 
Interest Expense N/A N/A N/A N/A 
Income Before Tax ($6,224,000) ($5,670,000) ($4,003,600) ($13,494,100) 
    Income Tax Expense N/A N/A N/A N/A 
    Equity Earnings Or Loss Unconsolidated Subsidiary N/A N/A N/A N/A 
    Minority Interest N/A N/A N/A N/A 
Net Income From Continuing Operations ($6,224,000) ($5,670,000) ($4,003,600) ($13,494,100) 
 
Nonrecurring Events 
    Discontinued Operations N/A N/A N/A N/A 
    Extraordinary Items N/A N/A N/A N/A 
    Effect Of Accounting Changes N/A N/A N/A N/A 
    Other Items N/A N/A N/A N/A 
Net Income ($6,224,000) ($5,670,000) ($4,003,600) ($13,494,100) 
    Preferred Stock And Other Adjustments N/A N/A N/A N/A 
 
Net Income Applicable To Common Shares ($6,224,000) ($5,670,000) ($4,003,600) ($13,494,100)